Y-mAbs Therapeutics Agrees to Acquisition by SERB Pharmaceuticals

Cooley represented Y-mAbs Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, in regard to its approximately $412 million acquisition by SERB Pharmaceuticals.